CClinicalTrials.gg
RecruitingNCT07435012MATTUpdated Mar 16, 2026

Androgenic Alopecia TH07 Clinical Trial

A Phase 3 interventional study of TH07 and TH07 in Androgenic Alopecia, sponsored by Triple Hair Inc. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Triple Hair Inc · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.

Read the detailed description

The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.

TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.

Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.

The treatment will be applied daily (once or twice) for 24 weeks.

02

Conditions studied

  • Androgenic Alopecia

Browse trials for

Keywords

  • Hair Loss
  • Hair growth
  • Androgenic Alopecia
  • Balding
03

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Males, 18 to 49 years of age on the date of enrollment.
  • Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
  • Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
  • Not administered any systemic or topical treatment for AGA during the last 90 days.
  • Willing to comply with the following restrictions for the duration of trial participation:

    1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
    2. Hair dyes, hair texturizers, relaxers etc.
    3. Any new vitamins or nutritional supplements that are currently not being administered.
    4. Tattooing in the trial target area.
    5. Blood donations.
    6. OTC hair restorers.
    7. Do not expose your pregnant partner to your hands/skin where the drug might be present.
    8. Participation in any other drug or device trials during the course of this trial.

      Note: However, the following shall be permissible:

    9. Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
    10. Current regimen (if any) of vitamins and nutritional supplements.
  • Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.
  • Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.

Exclusion criteria

Exclusion Criteria:

  • History of scalp treatment including though not limited to any of the following:

    1. Hair transplant or extension surgery.
    2. Hair weaving.
    3. Laser or light therapy on the scalp in the last 6 months.
    4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.

    5-Any other surgical treatment for hair loss

  • Any of the following hair styles:

    1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.

  • Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
  • Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
  • History or likelihood of use of any of the specified medicines.
  • History or clinical diagnosis of any of the specified medical conditions.
  • Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.
  • Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Arm A

    All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks

    Drug: TH07

  • Experimental
    Arm B

    All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks

    Drug: TH07

  • Active comparator
    Arm C

    All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks

    Drug: Minoxidil 5% Topical Solution

  • Placebo comparator
    Arm D

    All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks

    Other: Placebo

Interventions

  • DrugTH07

    TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day

  • DrugTH07

    * TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day

  • DrugMinoxidil 5% Topical Solution

    Minoxidil 5%; topical solution; twice a day

  • OtherPlacebo

    Placebo; topical solution; twice a day

05

What researchers measure

Primary outcomes

  1. Non-vellus hair count

    Number of hair in the matched target area measured by phototrichogram

    Time frame: Baseline and week 24

Secondary outcomes

  1. Hair diameter and cumulative hair thickness

    hair thickness is defined as average hair diameter \* hair count in the matched target area / size of matched target area (mm/cm2)

    Time frame: Baseline and week 24

  2. Subject-reported improvement

    self-assessment questionnaire

    Time frame: week 24

  3. Non-vellus hair count

    in the matched target area by phototrichogram between TH07 twice daily, TH07 once daily, and placebo

    Time frame: Baseline and week 24

  4. Incidence of treatment related adverse events.

    reporting of adverse events and serious adverse events

    Time frame: through study completion, average 28 weeks

06

Study locations

1 of 1 sites recruiting
  • YVR Aesthetic Training and Study Centre.
    Vancouver, British Columbia V5Z1H2, Canada
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07435012
Lead sponsor
Triple Hair Inc
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

Edouard AL-Chami
Contact
ealchami@triplehair.ca
647-453-3253
Lori Hebert
Contact
lhebert@triplehair.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion